FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have obesity
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the first medication for certain patients with the condition.
Weight Loss Drug Zepbound Could Treat Sleep Apnea Without a CPAP or Surgery
GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. Now, new research suggests Eli Lilly's weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality.
Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients
Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or tirzepatide, is the first and only prescription medicine for adults suffering from this condition.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.
News Medical on MSN25d
Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication
Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.
Health on MSN11d
Study Finds Nearly Half of People on Obesity Drugs Drink Less—But Do Scientists Know Why?
New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...
The Washington Post29d
Medicare proposes covering weight-loss drugs, teeing up clash with RFK Jr.
The American Academy of Family Physicians, the American Medical Association and other medical groups have called for expanding insurance coverage for anti-obesity medication, with physicians ...
Hosted on MSN2d
The city where the most people have tried injectable weight loss medications—and see the rest of the top 50
The market for injectable weight loss medications has experienced rapid growth. Goldman Sachs Research predicts the global ...
News Medical20d
Anti-obesity medications could help treat alcohol use disorders
Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.
Texas Public Radio22d
Dizzy after one drink? Social drinkers on obesity drugs lose the taste for alcohol
A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...
FoodNavigator13d
Could GLP-1 drugs curb alcohol consumption?
Now, research from Henry Ford Health, has found that weight-loss drugs, including GLP-1, could also impact alcohol ...
EurekAlert!29d
Alcohol use and antiobesity medication treatment
This cohort study among individuals participating in a weight loss program found that nearly half of those consuming alcohol at baseline decreased their alcohol use after anti-obesity medication ...
Benzinga.com22d
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
The study analyzed data from 14,053 eligible participants if they started using an anti-obesity medication between January 2022 and August 2023 and refilled the same medication during October or ...
Sandoz Boss Warns There’s a Climate Cost of Obesity Wonder Drugs
Richard Saynor sees opportunity in copying cutting-edge medication and extols the merits of being boring. Richard Saynor ...